Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 5/20 | 0.70 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.70 |
| ▸ | NAMPT | P43490 | 6/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | BRAF | P15056 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15093435 | 0.89 | NAMPT (0.68) | CYP11B2CYP11B1NAMPTLMNAHIF1A | |
| SCHEMBL789916 | 0.86 | EPHX2 (0.65) | CYP11B2CYP11B1NAMPTLMNAMEN1 | |
| SCHEMBL789589 | 0.86 | RAB9A (0.70) | CYP11B2CYP11B1NAMPTLMNAMEN1 | |
| SCHEMBL789647 | 0.85 | CYP11B1 (0.71) | CYP11B2CYP11B1LMNAMEN1KMT2A | |
| SCHEMBL790263 | 0.84 | LMNA (0.61) | CYP11B2CYP11B1NAMPTLMNAHIF1A | |
| SCHEMBL10978857 | 0.83 | CYP11B1 (1.00) | CYP11B2CYP11B1NAMPTLMNAMEN1 | |
| SCHEMBL789978 | 0.81 | LMNA (0.64) | CYP11B2CYP11B1NAMPTLMNASMN1; SMN2 | |
| SCHEMBL790944 | 0.81 | NAMPT (0.55) | CYP11B2CYP11B1NAMPTLMNAHIF1A | |
| SCHEMBL790983 | 0.79 | CYP11B1 (0.71) | CYP11B2CYP11B1NAMPTLMNAMEN1 | |
| SCHEMBL12707716 | 0.79 | LMNA (0.73) | CYP11B2CYP11B1NAMPTLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2615917-A2 | PYRIDINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS III | BASF SE (DE) | 2013-07-24 | — | — | EP | disclosed |
| US-20130180014-A1 | Pyridine Compounds for Controlling Invertebrate Pests III | BASF SE (DE) | 2013-07-11 | — | — | US | disclosed |
| WO-2012034959-A2 | PYRIDINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS III | BASF SE (DE) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130180014-A1 | Pyridine Compounds for Controlling Invertebrate Pests III | CHRM1, CHRM2, GRIN2C | CYP11B2 308/4885CYP11B1 396/4885NAMPT 4575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.